Long-Term Outcomes in Patients with Diabetes Mellitus Related to Prolonging Clopidogrel More Than 12 Months after Coronary Stenting

Journal of the American College of Cardiology

Volumn 66, Issue 10, 2015, Pages 1091-1101

  Thukkani, Arun K ^a,b   Agrawal, Kush ^a,c   Prince, Lillian ^d   Smoot, Kyle J ^d   Dufour, Alyssa B ^d,e   Cho, Kelly ^d   Gagnon, David R ^d   Sokolovskaya, Galina ^d   Ly, Samantha ^a   Temiyasathit, Sara ^a   Faxon, David P ^a,b,f   Gaziano, J Michael ^a,b,d,f   Kinlay, Scott ^a,b,f  

^a VA BOSTON HEALTHCARE SYSTEM   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c BOSTON MEDICAL CENTER   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e Hebrew Senior Life   (United States)

^f HARVARD MEDICAL SCHOOL   (United States)

Author keywords

clopidogrel; diabetes mellitus; long term outcomes; percutaneous coronary interventions

Indexed keywords

CLOPIDOGREL; INSULIN; ANTITHROMBOCYTIC AGENT; TICLOPIDINE;

ADULT; ARTICLE; BARE METAL STENT; BLEEDING; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY STENTING; DEATH; DIABETES MELLITUS; DRUG EFFECT; DRUG ELUTING STENT; DRUG USE; FEMALE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HIGH RISK PATIENT; HUMAN; HYPERTENSION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; RISK FACTOR; RISK REDUCTION; SMOKING; TREATMENT DURATION; AGED; ANALOGS AND DERIVATIVES; ANALYSIS OF VARIANCE; CAUSE OF DEATH; COHORT ANALYSIS; COMPARATIVE STUDY; COMPLICATION; CORONARY ARTERY DISEASE; DRUG ADMINISTRATION; EVALUATION STUDY; FACTUAL DATABASE; FOLLOW UP; INSURANCE; MEDICARE; MIDDLE AGED; MULTIVARIATE ANALYSIS; POSTOPERATIVE CARE; PROCEDURES; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; STATISTICS AND NUMERICAL DATA; SURVIVAL RATE; TIME; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME; UNITED STATES;

AGED; ANALYSIS OF VARIANCE; ANGIOPLASTY, BALLOON, CORONARY; CAUSE OF DEATH; COHORT STUDIES; CORONARY ARTERY DISEASE; DATABASES, FACTUAL; DIABETES MELLITUS; DRUG ADMINISTRATION SCHEDULE; DRUG-ELUTING STENTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; INSULIN; LONG-TERM CARE; MALE; MEDICARE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PLATELET AGGREGATION INHIBITORS; POSTOPERATIVE CARE; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; TICLOPIDINE; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES; VETERANS DISABILITY CLAIMS;

EID: 84940524533     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2015.06.1339     Document Type: Article

References (25)

1. F.G. Kushner, M. Hand, S.C. Smith Jr., and et al. 2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines J Am Coll Cardiol 54 2009 2205 2241
2. K.N. Garratt, W.D. Weaver, R.D. Jenkins, and et al. Prasugrel plus aspirin beyond 12 months is associated with improved outcomes after Taxus Liberte paclitaxel-eluting coronary stent placement Circulation 131 2015 62 73
3. L. Mauri, D.J. Kereiakes, R.W. Yeh, and et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents N Engl J Med 371 2014 2155 2166
4. F. Feres, R.A. Costa, and D.L. Bhatt Dual antiplatelet therapy after stent implantation-reply JAMA 311 2014 1446 1447
5. H.C. Gwon, J.Y. Hahn, K.W. Park, and et al. Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss after Stenting (EXCELLENT) randomized, multicenter study Circulation 125 2012 505 513
6. B.K. Kim, M.K. Hong, D.H. Shin, and et al. A new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation) J Am Coll Cardiol 60 2012 1340 1348
7. S.J. Park, D.W. Park, Y.H. Kim, and et al. Duration of dual antiplatelet therapy after implantation of drug-eluting stents N Engl J Med 362 2010 1374 1382
8. M. Valgimigli, G. Campo, M. Monti, and et al. Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial Circulation 125 2012 2015 2026
9. A. Colombo, A. Chieffo, A. Frasheri, and et al. Second-generation drug-eluting stent implantation followed by 6- versus 12-month dual antiplatelet therapy: The SECURITY randomized clinical trial J Am Coll Cardiol 64 2014 2086 2097
10. M. Gilard, P. Barragan, A.A. Noryani, and et al. Six-month versus 24-month dual antiplatelet therapy after implantation of drug eluting stents in patients non-resistant to aspirin: ITALIC, a randomized multicenter trial J Am Coll Cardiol 65 2015 777 786
11. A. Colombo, and A. Chieffo Dual antiplatelet therapy after drug-eluting stents - how long to treat? N Engl J Med 371 2014 2225 2226
12. A. Abizaid, R. Kornowski, G.S. Mintz, and et al. The influence of diabetes mellitus on acute and late clinical outcomes following coronary stent implantation J Am Coll Cardiol 32 1998 584 589
13. S. Elezi, A. Kastrati, J. Pache, and et al. Diabetes mellitus and the clinical and angiographic outcome after coronary stent placement J Am Coll Cardiol 32 1998 1866 1873
14. I. Iakovou, T. Schmidt, E. Bonizzoni, and et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents JAMA 293 2005 2126 2130
15. D.P. Faxon, E. Lawler, M. Young, and et al. Prolonged clopidogrel use after bare metal and drug-eluting stent placement: the Veterans Administration drug-eluting stent study Circ Cardiovasc Interv 5 2012 372 380
16. A.K. Jha, J.B. Perlin, M.A. Steinman, and et al. Quality of ambulatory care for women and men in the Veterans Affairs Health Care System J Gen Intern Med 20 2005 762 765
17. S. Elmariah, L. Mauri, G. Doros, and et al. Extended duration dual antiplatelet therapy and mortality: a systematic review and meta-analysis Lancet 385 2015 792 798
18. H. Bulluck, C.S. Kwok, A.D. Ryding, and Y.K. Loke Safety of short-term dual antiplatelet therapy after drug-eluting stents: An updated meta-analysis with direct and adjusted indirect comparison of randomized control trials Int J Cardiol 181 2015 331 339
19. S. Cassese, R.A. Byrne, G. Ndrepepa, and et al. Prolonged dual antiplatelet therapy after drug-eluting stenting: meta-analysis of randomized trials Clin Res Cardiol 2015 Apr 23 [E-pub ahead of print]
20. G. Giustino, U. Baber, S. Sartori, and et al. Duration of dual antiplatelet therapy after drug-eluting stent implantation: a systematic review and meta-analysis of randomized controlled trials J Am Coll Cardiol 65 2015 1298 1310
21. E.P. Navarese, F. Andreotti, V. Schulze, and et al. Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug eluting stents: meta-analysis of randomised controlled trials BMJ 350 2015 h1618
22. T. Palmerini, U. Benedetto, L. Bacchi-Reggiani, and et al. Mortality in patients treated with extended duration dual antiplatelet therapy after drug-eluting stent implantation: a pairwise and Bayesian network meta-analysis of randomised trials Lancet 385 2015 2371 2382
23. T. Palmerini, D. Sangiorgi, M. Valgimigli, and et al. Short- versus long-term dual antiplatelet therapy after drug-eluting stent implantation: an individual patient data pairwise and network meta-analysis J Am Coll Cardiol 65 2015 1092 1102
24. R.W. Yeh, D.J. Kereiakes, P.G. Steg, and et al. Benefits and risks of extended duration dual antiplatelet therapy after PCI in patients with and without acute myocardial infarction J Am Coll Cardiol 65 2015 2211 2221
25. S.D. Wiviott, E. Braunwald, D.J. Angiolillo, and et al. Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38 Circulation 118 2008 1626 1636